South Delhi Pharma, New Delhi, India
TAVALISSE ™ (fostamatinib disodium hexahydrate) tablets, for oral use.
Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call 9891296838 or Email email@example.com to discuss.
TAVALISSE is a prescription medicine. TAVALISSE is used to treat blood disorder known as chronic immune thrombocytopenia-ITP.
INDICATIONS AND USAGE
TAVALISSE is a kinase inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.
DOSAGE FORMS & STRENGTHS
Tablets: 100 mg, 150 mg
Manufactured By: Rigel Pharmaceuticals, Inc.
Prescribing Information URL: Click Here
South Delhi Pharma can facilitate the supply of “TAVALISSE ™ (fostamatinib disodium hexahydrate) tablets” to all locations in India and other part of countries after fulfilling the legal requirement (if applicable). All Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from South Delhi Pharma.
Get In Touch
Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.
The SDM is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.
M:+91-9891296838 / P:+91-11- 26532129
Fostamatinib, sold under the brand names Tavalisse and Tavlesse, is a tyrosine kinase inhibitor medication for the treatment of chronic immune thrombocytopenia (ITP).
Fostamatinib is a drug used to treat adults with low platelet count due to chronic immune thrombocytopenia (ITP) when a prior treatment for ITP has not worked well enough. Chronic immune thrombocytopenia is an autoimmune bleeding disorder where the blood doesn't clot as it should because of a low platelet count.
The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.